The fate of Johnson & Johnson’s latest push to use bankruptcy courts to end thousands of cancer lawsuits tied to its iconic baby powder now hinges on a high-stakes trial in January. After months of wrangling, a federal judge in Houston early next year will decide whether J&J’s bid to quickly settle the claims with … Read more
By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company … Read more
There are multiple layers to a Clans battle. There is your actual movement, which can take getting used to, with your legs moving on their own trajectory while you swivel your torso. There is your squad and how they’re deployed, which takes up many of your background thought cycles. And there is your mech, its heating levels, … Read more
By Brad Sorensen, CFA OTC:BSEM READ THE FULL BSEM RESEARCH REPORT BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company states its mission is “to discover, develop and produce the most effective regenerative medicine … Read more
By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT SIGNIFICANT OPERATIONAL UPDATES Administration is implementing a important value slicing program with the aim of making certain that Volition (NYSE:VNRX) is money move impartial in 2025. Value reductions taken throughout 1H 2024 resulted in a 15.9% decline in working bills. Value discount measures have … Read more